Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands

E. Boon, M.H. Valstar, W.T.A. van der Graaf, E. Bloemena, S.M. Willems, C.A. Meeuwis, P.J. Slootweg, L.A. Smit, M.A.W. Merkx, R.P. Takes, J.H.A.M. Kaanders, P.J.T.A. Groenen, U.E. Flucke, C.M.L. van Herpen

Research output: Contribution to JournalArticleAcademicpeer-review


Objectives: In 2010, a new subtype of salivary gland cancer (SGC), (mammary analogue) secretory carcinoma (SC), was defined, characterized by the ETV6-NTRK3 fusion gene. As clinical behavior and outcome data of this histological subtype tumor are still sparse, we aimed to describe the clinicopathological course and outcome of a series of translocation positive SC patients.
Patient and methods: We re-evaluated the pathological diagnosis of a subset of SGCs, diagnosed in 4 of 8 Dutch head and neck centers. Subsequently, tumors with a morphological resemblance to SC were tested for the ETV6-NTRK3 fusion gene using RT-PCR. Furthermore, patients prospectively diagnosed with SC were included. The clinical characteristics and outcomes were retrieved from the patient files.
Results: Thirty-one patients with ETV6-NTRK3 fusion gene positive SC were included. The median age was 49 years, 17 patients (55%) were male. Eighteen tumors (58%) arose in the parotid gland. One patient presented with lymph node metastasis. All patients underwent tumor resection and 4 patients had a neck dissection. Four patients had re-resection and 15 patients (48%) received postoperative radiotherapy. One patient developed a local recurrence, no regional recurrences or distant metastases were observed. After a median follow-up of 49 months the 5- and 10-year overall survival were 95%, the 5- and 10-year disease free survival were 89%.
Conclusion: The clinical course of SC is favorable with a low rate of locoregional recurrence and excellent survival. Given the low incidence of nodal metastases, elective neck treatment, i.e. surgery and/or radiotherapy, does not seem to be indicated.
Original languageEnglish
Pages (from-to)29-33
JournalOral Oncology
Publication statusPublished - Jul 2018


Dive into the research topics of 'Clinicopathological characteristics and outcome of 31 patients with <em>ETV6-NTRK3</em> fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands'. Together they form a unique fingerprint.

Cite this